A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables

Published: 29 July 2021| Version 2 | DOI: 10.17632/b6sct48jmb.2
Contributor:
Brett King

Description

Supplementary Figures 1-7. Supplementary Tables 1-5

Files

Categories

Alopecia Areata, Janus Kinase

License